The Dutch biotech’s stock dropped about 10% Tuesday morning after the company reported that its injectableVyvgart Hytrulo ...
Aldeyra Therapeutics is planning to run another trial, in line with the regulator’s requirements, and is expecting top-line ...
Targeting TSLP may be a scalable approach across inflammatory conditions, said Truex. “One of the benefits of going after ...
The Ogsiveo tablets are the first approval therapy for the rare subtype of soft tissue sarcomas, which can lead to severe ...
Acelyrin on Monday announced that it will conduct a sweeping review of the development program for its investigational IL-17A ...
While XEN1101 failed to hit the primary endpoint in a Phase II trial, the Canadian company is “actively exploring” further ...
New data show the biologic significantly reduced exacerbations in chronic obstructive pulmonary disease, confirming positive ...
Pegozafermin showed statistically significant improvements in treating patients with nonalcoholic steatohepatitis, notching a ...
A year after exiting the U.S. market, GSK is setting the stage for the antibody-drug conjugate's possible return in ...
While Amgen and Mirati are widely viewed as frontrunners to win the first front line approval, analysts—and competitors—say ...
As companies clamor for a piece of the antibody-drug conjugate pie, experts pose the question: is it possible to replicate the success of Enhertu?
The biotech company has bought the global rights to an investigational oral CDK2 inhibitor from Ensem Therapeutics in a ...